CRSP - bluebird bio gains FDA approval of gene therapy lovo-cel for sickle cell disease
2023-12-08 11:39:48 ET
More on bluebird bio
- bluebird bio Isn't Priced For Success
- Buy bluebird bio's Lovo-Cel As It Transforms Sickle Cell Disease Treatment
- bluebird bio, Inc. (BLUE) Q3 2023 Earnings Call Transcript
- Morgan Stanley ups bluebird to equal weight ahead of FDA decision
- bluebird bio GAAP EPS of -$0.66 beats by $0.01, revenue of $12.39M misses by $1.02M
For further details see:
bluebird bio gains FDA approval of gene therapy lovo-cel for sickle cell disease